Anti Alzheimer’s drug, clash between the FDA and the US Congress on costs and effectiveness

Another harsh attack on research against Alzheimer’s disease, which risks leaving its mark above all on the stone guest of this affair. That is: the patients. It is an unprecedented attack that the US Congress has launched against the Food and Drug Administration (FDA), the body (direct emanation of the Department of Health and Human Services) called to give the last word before the release marketing of drugs and foods for therapeutic purposes.

According to